DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response

[1]  D. Hanahan Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[2]  Gary D Bader,et al.  Functional genomic landscape of cancer-intrinsic evasion of killing by T cells , 2020, Nature.

[3]  Ryan D. Chow,et al.  CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. , 2020, Cancer discovery.

[4]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[5]  P. Robson,et al.  Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer , 2020, Nature Cancer.

[6]  Zhiyong Guo,et al.  Upregulated Seizure-Related 6 Homolog-Like 2 Is a Prognostic Predictor of Hepatocellular Carcinoma , 2020, Disease markers.

[7]  Xiaozhong Wang,et al.  Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells , 2020, Nature Communications.

[8]  P. Hertzog,et al.  Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer , 2020, Clinical & translational immunology.

[9]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[10]  J. Herman,et al.  Epigenetic heterogeneity in cancer , 2019, Biomarker Research.

[11]  F. Rossi,et al.  Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs , 2019, Breast Cancer Research.

[12]  Martin L. Miller,et al.  UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma , 2019, Cell.

[13]  T. Aittokallio,et al.  Improved detection of differentially represented DNA barcodes for high-throughput lineage phenomics , 2019, bioRxiv.

[14]  Jeffrey T. Chang,et al.  Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state , 2019, Science Translational Medicine.

[15]  Daniel L. Cameron,et al.  Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer , 2019, Nature Communications.

[16]  S. Miller,et al.  Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis , 2019, Brain : a journal of neurology.

[17]  M. Kunitski,et al.  Double-slit photoelectron interference in strong-field ionization of the neon dimer , 2018, Nature Communications.

[18]  P. Bousso,et al.  The immune system profoundly restricts intratumor genetic heterogeneity , 2018, Science Immunology.

[19]  Jeffrey T. Chang,et al.  High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer , 2018, Nature Communications.

[20]  F. Marincola,et al.  Evolution of Metastases in Space and Time under Immune Selection , 2018, Cell.

[21]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[22]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[23]  Ziwei Wang,et al.  HOXA5 is a tumor suppressor gene that is decreased in gastric cancer , 2018, Oncology reports.

[24]  Wyeth W. Wasserman,et al.  Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer , 2018, Cell.

[25]  Aroop Sircar,et al.  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β , 2018, Science Translational Medicine.

[26]  Zlatko Trajanoski,et al.  Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution , 2018, Nature Communications.

[27]  C. Zahnow,et al.  DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer , 2018, Nature Communications.

[28]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[29]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[30]  V. Chekhonin,et al.  Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer , 2017, Scientific Reports.

[31]  John G. Doench,et al.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.

[32]  H. Ljunggren,et al.  Natural killer cell-mediated immunosurveillance of human cancer. , 2017, Seminars in immunology.

[33]  Aaron T. L. Lun,et al.  No counts, no variance: allowing for loss of degrees of freedom when assessing biological variability from RNA-seq data , 2017, Statistical applications in genetics and molecular biology.

[34]  M. Thangaraju,et al.  Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade , 2017, Nature Communications.

[35]  Zhiping Weng,et al.  Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. , 2017, Gastroenterology.

[36]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[37]  L. Ellies,et al.  Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis , 2017, Oncoimmunology.

[38]  Carlos Caldas,et al.  Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study , 2016, PLoS medicine.

[39]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[40]  C. Zahnow,et al.  Combining Epigenetic and Immunotherapy to Combat Cancer. , 2016, Cancer research.

[41]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[42]  Michael A. Langston,et al.  EntropyExplorer: an R package for computing and comparing differential Shannon entropy, differential coefficient of variation and differential expression , 2015, BMC Research Notes.

[43]  S. Loi,et al.  Relevance of tumor-infiltrating lymphocytes in breast cancer , 2015, BMC Medicine.

[44]  Steffen Dickopf,et al.  A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis , 2015, Nature.

[45]  Joshua M. Korn,et al.  Studying clonal dynamics in response to cancer therapy using high-complexity barcoding , 2015, Nature Medicine.

[46]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[47]  P. Hauser,et al.  Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression , 2014, PloS one.

[48]  P. Argani,et al.  Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78 , 2013, Clinical Cancer Research.

[49]  Weisan Chen,et al.  An optimized method for establishing high purity murine CD8+ T cell cultures. , 2013, Journal of immunological methods.

[50]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[51]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[52]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[53]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[54]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[55]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[56]  S. Hochreiter,et al.  cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate , 2012, Nucleic acids research.

[57]  F. Bertucci,et al.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.

[58]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[59]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[60]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[61]  J. Paul,et al.  New Dimensions , 2011 .

[62]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[63]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[64]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[65]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[66]  Yusuke Nakamura,et al.  Characterization of SEZ6L2 cell‐surface protein as a novel prognostic marker for lung cancer , 2006, Cancer science.

[67]  D. Middleton,et al.  Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.

[68]  G. Collins The next generation. , 2006, Scientific American.

[69]  M. Cristofanilli Circulating Tumor Cells in Patients With Breast Cancer Dormancy , 2005 .

[70]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[71]  V. Cicinnati,et al.  Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope , 2000, Gene Therapy.

[72]  J. Altman,et al.  Mouse CD94/NKG2A Is a Natural Killer Cell Receptor for the Nonclassical Major Histocompatibility Complex (MHC) Class I Molecule Qa-1b , 1998, The Journal of experimental medicine.

[73]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.